AI주식인사이트AI Stock Insight
C

셀레믹스

331920KOSDAQ기초 의약물질 제조업

48.5 / 100

Reference Date: 2026-07-24

Financial Score19.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 18.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellomics is a company specializing in DNA sequencing and molecular cloning technologies based on molecular biology, utilizing its innovative MSSIC (Massively Separated and Sequence Identified Cloning) technology to enable low-cost, high-throughput analysis. The company offers key products such as Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions, which are widely used in healthcare, pharmaceuticals, agriculture, and other fields.

Number of Employees

41people

Average Salary

60.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
4.82Industry Average 1.260.0Point

3.8x industry avg (risky)

ROE
-16.08Industry Average -6.033.5Point

2.7x industry avg (excellent)

Debt Ratio
0.48Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼6.0% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.8% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 6.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position5.0Point

52w mid range (46%)

Current 9,920Won52-week high 18,20052-week low 2,580
1-month return0.0Point

1m -18.22% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-07-21
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-07-13
  • Neutral임시주주총회결과2026-07-13